Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole effect on RO4602522 pharmacokinetics in healthy male volunteers
NL-OMON36948Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sembragiline and ketoconazole in Alzheimer's disease (AD) (2 arms), sponsored by Roche. Primary endpoints: Pharmacokinetics of RO4602522 and metabolites and Urinary pharmacokinetics of RO4602522. Started Jun 2012; status: active, not recruiting.
02
Drugs
sembragilineketoconazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON36948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36948.